The NFAM 2002 founder's awards for excellence in the field of complementary & alternative medicine

Townsend Letter for Doctors and Patients,  Feb-March, 2003  

• E-mail
• Print
• Link

Candace Campbell

Executive Director of the national advocacy organization, The American Association for Health Freedom, Ms. Campbell has lobbied intensively for the passage of the "Access to Medical Treatment Act" and her organization functions as the foremost political voice protecting the rights of complementary and alternative healthcare practitioners.

Larry Dossey, MD

Executive editor of the peer-reviewed journal, Alternative Therapies in Health & Medicine, Dr. Dossey is also the author of 9 books on the mergn the body. It also has been shown to reduce the side-effects of radiation and chemotherapy. We hope this new enhanced lifespan data will lead more doctors and patients to seriously explore complementary medicine to combine natural supplements with conventional therapies." Lane added.

Takahara's research also found a striking correlation between survival rates and Natural Killer (NK) cell activity, which has been shown in several previous clinical studies to be increased as much as 300% with MGN3 supplementation. In the study, patients whose NK cell activity increased 40% or more during the study recorded a survival rate of 81%.

MGN3, a patented formula of rice bran hydrolyzed with Shiitake mushroom extracts, has been shown in other in vivo/in vitro clinical trials to significantly enhance virtually every critical component of the immune system. It triples NK cell activity, the immune system's "elite troops" that are the first line of defense against health threats. MGN3 is clinically proven to boost B and T cell activity by 200-250% and heighten cytokine production as well.

MGN3's research has been presented at renowned medical conferences and published in respected peer-reviewed journals. The long-term efficacy of MGN3 has been clinically proven for a period of five years. Unlike many natural and pharmaceutical biological response modifiers, MGN3 does not cause "hyporesponsiveness," a brief period of effective immune enhancement followed by a significant drop in immune function despite the continuation of treatment. Many of the clinical trials on MGN3 have been conducted or overseen by Mamdooh Ghoneum, PhD, a UCLA immunologist who pioneered the arabinoxylane compound several decades ago.

For comprehensive research results, go to www.publishedresearch.com.

About LaneLabs

LaneLabs is a leader in innovative, well researched, proprietary natural products for human health. The company dedicates approximately 10% of its revenue annually to the research and development of promising natural therapies. For more information on the LaneLabs family of products, visit them on the web at www.lanelabs.com.

COPYRIGHT 2003 The Townsend Letter Group
COPYRIGHT 2003 Gale Group